Organigram to Acquire German Sanity Group for €113.4M Plus €113.8M Earnouts
Organigram will pay Sanity shareholders 113.4 million euros (80 million cash, 33.4 million shares) plus earnouts up to 113.8 million, financed by cash, a credit facility and a 65.2 million CAD investment from British American Tobacco. The acquisition expands Organigram’s footprint in Europe and is expected to be accretive after Sanity’s positive 2025 EBITDA.
1. Deal Terms
Organigram agreed to pay Sanity shareholders 113.4 million euros, comprising 80 million in cash and 33.4 million in shares, with earnouts up to 113.8 million euros (20 million cash, 93.8 million shares). British American Tobacco has elected to receive share consideration for its Sanity stake.
2. Financing Structure
Organigram plans to fund the transaction using cash on hand, proceeds from a new credit facility and a 65.2 million Canadian dollar equity investment from British American Tobacco to cover the cash component.
3. Strategic Rationale
The acquisition will position Organigram as a pure-play global cannabis company with a significant footprint in major European markets. Organigram expects to leverage Sanity’s positive 2025 EBITDA to drive revenue growth and profitability.
4. Stock Technicals
Organigram shares jumped 7.09% in premarket trading following the announcement and are currently trading 13.3% below their 20-day SMA and 21.8% below their 100-day SMA. The RSI of 31.75 and a MACD below its signal line indicate mixed momentum, with resistance at $1.50 and support at $1.00.